NEW YORK (GenomeWeb News) - Multispan and Promega said yesterday that they will co-develop assay tools for G-protein coupled receptor screening using Multispan’s GPCR cell lines and Promega’s bioluminescent technology.
The companies said that the initial tools to be developed under the agreement will use Promega’s cAMP-Glo Assay technology for signal quantification. The partners said they will develop additional tools for “cell-based assay detection,” but did not provide further details.
John Watson, marketing director for pharma and biotech at Promega, said that the protocols developed under the partnership should reduce assay-development times “from months to days.”
Financial details of the agreement were not disclosed.